Abstract Number: 2101 • ACR Convergence 2025
LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Background/Purpose: When evaluating new osteoarthritis (OA) therapies, we need to understand their clinical meaningfulness. LEVI-04, a first-in-class p75 neurotrophin receptor-Fc fusion protein that primarily inhibits…Abstract Number: 0397 • ACR Convergence 2025
Paediatric uveitis – Retrospective comparison of cataract surgery outcomes with or without intraocular lens implantation from two tertiary centres in United Kingdom
Background/Purpose: Cataract is one of the most common and visually debilitating complications of paediatric uveitis developing as a consequence of chronic inflammation and steroid use.…Abstract Number: 2008 • ACR Convergence 2025
Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
Background/Purpose: As reported in Cell Press journals,1,2 intestinal commensal purine-degrading bacteria anaerobically degrade urate to anti-inflammatory short chain fatty acids, including butyrate, and thus may…Abstract Number: 0319 • ACR Convergence 2025
Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability and the most common rheumatological condition worldwide. Weight management has been recognized as a key…Abstract Number: 1914 • ACR Convergence 2025
Performance Comparison of Artificial Intelligence tools ChatGPT, Bing AI, and Google Bard for Clinical Rheumatology Decision Support: When AI Talks Rheumatology
Background/Purpose: Artificial intelligence (AI) has shown promise as a tool to assist in clinical decision-making. Given the complex nature of autoimmune pathologies and the critical…Abstract Number: 0298 • ACR Convergence 2025
Inter-rater Reliability of Hand-Held Dynamometry in Patients with Idiopathic Inflammatory Myopathy
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by symmetrical proximal muscle weakness. Accurate and reliable assessment of muscle strength is important for diagnosis, monitoring, and…Abstract Number: 1629 • ACR Convergence 2025
Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
Background/Purpose: A previous post hoc analysis of frail (defined by claims-based frailty index [CFI] ≥0.2) patients with PMR on second line (2L) and 3L treatment…Abstract Number: 0165 • ACR Convergence 2025
Per-Protocol Analysis of the Effectiveness of GLP1 Agonists Against SGLT2 Inhibitors on Osteoarthritis Outcomes
Background/Purpose: Anti-diabetic medications often have effects on other conditions. GLP1 agonists (GLP1a) have shown protective effects on OA outcomes in trials and short-term trial emulations,…Abstract Number: 1362 • ACR Convergence 2024
Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Background/Purpose: Network meta-analyses of phase 3 clinical trial data involving JAK inhibitor (JAKi)-treated patients with RA and an inadequate response to conventional synthetic DMARDs showed…Abstract Number: 1534 • ACR Convergence 2024
Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have nephroprotective and cardioprotective benefits and may have a role in lupus nephritis (LN) treatment. 2023 EULAR SLE treatment guidelines…Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…Abstract Number: 2022 • ACR Convergence 2024
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…Abstract Number: 2075 • ACR Convergence 2024
A Retrospective Cohort Study Assessing Outcomes and Safety in Patients Receiving Low Dose vs High Dose Cyclophosphamide in Myositis Interstitial Lung Disease (ILD)
Background/Purpose: ILD is associated with poor survival in patients with idiopathic inflammatory myopathies (IIM). Cyclophosphamide is often used in the management of myositis associated ILD…Abstract Number: 2164 • ACR Convergence 2024
Boosting Adherence to “Sick Day Rules”: A Quality Improvement Study in Rheumatology Outpatients on Immunosuppressive Medications, Results of Post-intervention Phase
Background/Purpose: Acute infections are common among rheumatology outpatients receiving immunosuppressive medications (IS). Expert guidance advises pausing IS during acute infection, resuming only when clinically improved,…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »
